1. Introduction {#sec0005}
===============

Porcine reproductive and respiratory syndrome virus (PRRSV) is the etiologic agent of porcine reproductive and respiratory syndrome (PRRS), commonly known as "blue ear disease." It is the main respiratory disease affecting swine and one of the costliest for the world's pork producers. PRRSV is a 15 kb single-stranded, positive-sense enveloped RNA virus, and its genome encodes 14 nonstructural (nsps) and eight structural proteins ([@bib0020],[@bib0030]; [@bib0125]). Moreover, PRRSV infects pigs of all ages, causing fever, lethargy, inappetence, and respiratory distress ([@bib0090]). The infection of pregnant sows often results in abortion, stillbirth, and mummified fetuses. Infected piglets often present with weakness, watery diarrhea, severe respiratory symptoms, and even death ([@bib0015]). PRRSV was initially isolated in China in 1995, and the highly pathogenic strain (HP-PRRSV) was isolated in China in 2006 ([@bib0170]), and it has since spread widely, taking a large economic toll on China's pork producers. The main clinical symptoms of HP-PRRSV include high fever, dyspnea, and rubefaction, whereas the primary pathological symptom is interstitial pneumonia ([@bib0125]; [@bib0170]). Since 2012, NADC30-like strains have become more prevalent in China, increasing the difficulty of prevention and control ([@bib0115]; [@bib0190], [@bib0195]).

The innate immune response is the host's first line of defense against pathogen invasion. In general, interferons (IFNs) are one of the earliest cytokines produced following viral invasion. Initially, host pattern recognition receptors (PRRs) recognize pathogens and activate I type IFN signaling via IRF3 and NF-κB to produce multiple interferon-stimulated proteins to inhibit viral infection ([@bib0210]). However, as an immunosuppressive virus, PRRSV has many immunosuppressive mechanisms of inhibiting the host innate and adaptive immune responses to support viral replication ([@bib0025]). PRRSV nsp1α inhibits IFN-β production by degrading CREB-binding protein (CBP) and suppressing NF-ĸB activation ([@bib0105]). In addition, nsp1β and nsp2 can hinder the activation of IRF3 to inhibit IFN-β expression ([@bib0010]; [@bib0120]). NF-κB-essential modulator (NEMO) is an essential molecule for NF-ĸB activation, and MAVS is an upstream molecule in the IFN-β pathway; PPRSV nsp4 can cleave these two molecules to decrease IFN-β production ([@bib0070]; [@bib0080]). Moreover, PRRSV infection can induce the apoptosis DC cells ([@bib0075]), reduce the expression of antigen presenting molecules on the surface of antigen presenting cells ([@bib0025]), inhibit the proliferation and differentiation of B and T cells ([@bib0150]), and promote the production of immunosuppressive cells (e.g., regulatory T cells) ([@bib0055]). In addition, the rapid mutation and recombination of PRRSV are associated with a substantial challenge to both viral prevention and control. Although there are several commercially available vaccines, their effectiveness is limited. Therefore, it is extremely important to study the pathogenesis of PRRSV further, which remains poorly understood.

PRRSV nucleocapsid protein is a multifunctional protein that is essential for viral replication. Thus, N protein is likely to be the target of host innate immune molecules for inhibiting viral propagation. [@bib0095] indicated that TRIM22 can reduce PRRSV replication through interacting with N protein nuclear localization signal (NLS). And MOV10 could co-localize with the PRRSV N protein in the cytoplasm and disturb the distribution of N protein in the cells, leading to the retention of N protein in the cytoplasm ([@bib0225]). In addition, [@bib0190], [@bib0195]) reported that SUMO E2 conjugating enzyme Ubc9 can interact with and SUMOylate N protein to regulate PRRSV replication.

Damage-associated molecular patterns (DAMPs) are biomolecules that can activate the innate immune response, as well as directly or indirectly initiate the adaptive immune response ([@bib0160]). Numerous DAMPs have been identified, including high mobility group box 1 (HMGB1), heat shock proteins (HSPs), and S100 proteins. These DAMPs may participate in viral replication, to some extent, using a variety of different means ([@bib0130], [@bib0135]; [@bib0175]). S100 calcium-binding protein A9 (S100A9) is a member of the S100 family of calcium-binding proteins. A recent study showed that S100A9 is a host restrictive factor that possesses antiviral activity against bovine viral diarrhea virus (BVDV) replication ([@bib0040]). In our previous proteomics study, we found that the expression of S100A9 was significantly increased in PRRSV-infected PAMs (data not shown); however, the role of S100A9 in PRRSV infection remains unknown. In this study, we report that S100A9 has significant antiviral activity against PRRSV replication, and interacts with the viral N protein at amino acid 78 of S100A9 and amino acids 36--37 of the viral N protein, respectively. These findings suggest a novel host antiviral mechanism against PRRSV.

2. Materials and methods {#sec0010}
========================

2.1. Cells and virus {#sec0015}
--------------------

Marc-145 cells, a monkey embryonic kidney cell line that is highly permissive for PRRSV, and HEK293T cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 10 % heat-inactivated fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin. The cells were incubated at 37 °C in a humidified atmosphere containing 5 % CO~2~. Porcine alveolar macrophages (PAMs) were obtained from five-week-old piglets, which were free of PRRSV, pseudorabies virus, porcine circovirus type 2, and classical swine fever virus. Moreover, the PAMs were maintained in Roswell Park Memorial Institute 1640 medium (RPMI 1640) (Invitrogen) containing 10 % FBS, 1 % non-essential amino acids (Invitrogen), 100 U/mL penicillin, and 100 μg/mL streptomycin. The cells were incubated in a 37 °C humidified atmosphere containing 5 % CO~2~. The classical PRRSV S1 strain (C-PRRSV) (GenBank accession No. [AF090173](ncbi-n:AF090173){#intr0005}) was obtained from clinical material in Jiangsu province in 1997. The BB0907 strain (GenBank accession No. [HQ315835](ncbi-n:HQ315835){#intr0010}) is a highly pathogenic strain of PRRSV (HP-PRRSV) that was isolated from clinical samples collected in Guangxi province, China, in 2009. The NADC30-like PRRSV strain, FJ1402 (GenBank accession No. [KX169191.1](ncbi-n:KX169191.1){#intr0015}), was isolated from clinical materials in Fujian province, China, in 2014. Recombinant virus rBB (36/37) was rescued from the infectious clone, pCMV-BB0907 (constructed in our laboratory), as previously described ([@bib0145]). The viruses were cultured and tittered in Marc-145 cells.

2.2. Antibodies and reagents {#sec0020}
----------------------------

Anti-HA, FLAG, and β-actin mouse monoclonal antibodies were purchased from Proteintech (USA, Chicago), and an anti-S100A9 rabbit polyclonal antibody was purchased from Abcam (Cambridge, UK). BAPTA, a specific intracellular Ca^2+^ chelating agent, was purchased from MedChemExpress (New Jersey, USA). PMSF was purchased from Solarbio (Beijing, China). The anti-PRRSV N protein mAb was prepared in our lab.

2.3. Plasmids and siRNA {#sec0025}
-----------------------

Total RNA was extracted from Marc-145 cells or PAMs, and used for cDNA synthesis. *S100A9* was amplified via PCR and cloned into the pCI-neo vector with a 3′ HA tag. Sequence verification of the resulting plasmid, pCI-S100A9-HA, was conducted by Genscript Biotechnology Co., Ltd. (Nanjing, China). The nucleotide sequence of *S100A9* was found to have a 98.2 % similarity to that in NCBI using DNAStar 8.0 software.

PRRSV genes were amplified from the BB0907 strain by PCR and cloned into the pCI-neo vector with a 3′ FLAG tag. Following the sequence verification of the resulting plasmids, all of the recombinant plasmids were transfected into HEK293T cells to verify that these proteins were efficiently expressed. However only Nsp1α, Nsp1β, Nsp4, Nsp5, Nsp7, Nsp9-12, GP5, M, and N proteins could be efficiently expressed (data not shown). Plasmids expressing the mutated PRRSV N protein, pCI-N\*-FLAG, were previously constructed in our lab ([@bib0145]). Fig. S1 presents a diagram of these mutated plasmids.

According to the key amino acid of human S100A9 reported at <https://www.uniprot.org/>, a series of mutated S100A9 plasmids were constructed. These constructs were created using a QuikChange® II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. All plasmids were efficiently expressed in 293T cells.

Three pairs of specific siRNAs for monkey or porcine *S100A9* and a non-specific control siRNA were designed by GenePharma (Shanghai, China). Macr-145 or PAM cells were transfected with siRNAs using Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen) according to the manufacturer's instructions. The siRNA sequences of monkey or porcine S100A9 used in this study are as follows, siRNA1, 5′-GAACCGGAGGGAAUUCAAATT-3′; siRNA2, 5′-GCAGCU GGAACGCAACAUATT-3′; siRNA3, 5′-GGACACAAAUGCAGACAAGTT-3′; and siRNA-1, 5′-GCAGAUGGAAUGCAGCAUATT-3′; siRNA-2, 5′-GCUGCCAAACUUUCUCAAGTT-3′; siRNA-3, 5′-*CGA AAUAAAGUCUCCCUCUTT*-3′.

2.4. Lentivirus packaging {#sec0030}
-------------------------

*S100A9* and *S100A9 (E78Q)* were cloned into the lentiviral expression plasmid, pCDH-CMV-MCS-EF1-GFP-Puro, (kindly provided by Professor HeBin, Illinois State University, USA), to generate recombinant plasmids. A recombinant plasmid and two packaging plasmids, psPAX2 and PMD2.G, were co-transfected into HEK293T cells at a ratio of 4:3:1, and the supernatants were collected at 48 h and 60 h after transfection, respectively. Viral supernatants were concentrated using a lentivirus concentration kit (Genomeditech Biotech Co., Ltd., Shanghai, China) according to the manufacturer's instructions. Viral titers were measured in HEK293T cells.

2.5. Western blotting analyses {#sec0035}
------------------------------

The cells were harvested using RIPA buffer containing PMSF. Samples were centrifuged at 12,000 × *g* for 5 min to remove the insoluble material. Supernatants were collected and their total protein concentration was measured using a BCA kit. Equal amounts of protein with 5× loading buffer were placed into a boiling water bath for 5 min and then loaded into the wells of a 10 % SDS-polyacrylamide gel, after which the separated proteins were transferred onto a nitrocellulose membrane. The membranes were blocked with 10 % nonfat milk for 2 h at room temperature (RT), and then incubated with primary antibodies for 2 h at RT. After washing, the membranes were incubated with a secondary antibody for 1 h at RT. The membranes were rinsed once again, and images were captured using Thermo Pierce ECL substrate with a Tanon5200 Chemi-Image system (Biotanon, Shanghai, China).

2.6. Quantitative real-time PCR {#sec0040}
-------------------------------

Total RNA Kit I (Omega Bio-tek, Shenzhen, China) was used to extract RNA from cells and synthesize the cDNA. qPCR was performed in an ABI QuantStudio 6 Systems (Applied Biosystems, Foster City, CA, USA) using a SYBR-Green RT-PCR Master Mix (Applied Biosystems). The PCR conditions were as follows: an initial denaturation for 5 min at 95 °C, followed by 40 cycles of 15 s at 95 °C, and 1 min at 60 °C. All of the primer sequences that were used are as follows, monkey *S100A9,* 5′-*GCTGGAACGCAACATAGAGA*-3′ *and* 5′-*CTGGTT CAGGGTGTCTTTGT*-3′; porcine *S100A9,* 5′-*CAACATCTTCCACCAGTACTCG*-3′ *and* 5′-*CATT AGTGTCCAGGTCTTCCAG*-3′; PRRSV N gene, 5′-AAACCAGTCCAGAGGCAAGG-3′ and 5′-TCAGTCGCAAGAGGGAAATG-3′; β-anctin, 5′-CTCCATCATGAAGTGCGACGT-3′ and 5′-GTGATCTCCTTCTGCATCCTGTC-3′. Duplicate samples of each transcript were analyzed, and the level of expression for all genes was normalized to that of β-actin. The results were calculated using the 2^-ΔΔCT^ method.

2.7. Immunoﬂuorescence assay {#sec0045}
----------------------------

Virus-infected and plasmid-transfected cells were fixed with 10 % formalin-PBS for 10--15 min at RT, rinsed with PBS, then permeabilized with prechilled acetone (−20 °C) for exactly 5 min. Cells were rinsed again and blocked with 1 % BSA-PBS for 1 h at RT. Cells were incubated with primary antibodies for 1 h at 37 °C, then washed three times with PBS, followed by an incubation with a fluorescence-labeled secondary antibody for 1 h at 37 °C. The cells were rinsed again, and the nuclei were stained with DAPI for 10 min at RT. Cells were observed using a confocal laser-scanning microscope (Zeiss LSM 510 system, Carl Zeiss AG, Oberkochen, Germany).

2.8. Immunoprecipitation {#sec0050}
------------------------

HEK293 T cells were seeded into six-well plates and cultured overnight, and the cells were co-transfected with pCI-S100A9-HA and pCI*-N-*FLAG or pCI-N\*-FLAG. At 24 h post-transfection, the cells were washed three times with PBS and then incubated with RIPA buffer for 10--15 min on ice. The cell lysates were collected and centrifuged at 10,000 × *g* for 10 min at 4 °C. Supernatants were transferred to fresh tubes on ice, and 1 μg of mouse IgG and 20 μL of protein A/G agarose (Santa Cruz Biotechnology, Texas, USA) were added to each tube. After incubation for 1 h at 4 °C, the samples were centrifuged at 1000 × *g* for 5 min at 4 °C to remove any beads. The supernatants were collected and an anti-HA (1:1000) antibody was added to each tube. After an incubation for 1 h at 4 °C, 20 μL protein A/G agarose was added to each sample and the incubation continued at 4 °C overnight. The immunoprecipitated proteins were collected by centrifugation at 1000 × *g* for 5 min at 4 °C. After washing three times in RIPA buffer, the immunoprecipitated proteins were resuspended in 100 μL RIPA for western blot analysis.

2.9. Ethics statement {#sec0055}
---------------------

All animal experiments were performed in accordance to the guidelines of the Institutional Animal Care and Ethics Committee of Nanjing Agricultural University (NAU) (Nanjing, Jiangsu, China). All animals were raised in the NAU animal facility, and all operations were performed in accordance with the International Guiding Principles for Biomedical Research Involving Animals.

2.10. Statistical analyses {#sec0060}
--------------------------

The signiﬁcance of the variability among groups was analyzed with GraphPad Prism 7.0 software (GraphPad, La Jolla, CA, USA) using a one-way analysis of variance or a Student\'s unpaired two-tailed test. Differences were considered to be statistically significant if P \< 0.05. Densitometric analyses were performed using Quantity One 4.6 software (Bio-Rad, Hercules, CA, USA).

3. Results {#sec0065}
==========

3.1. PRRSV infection stimulates S100A9 expression in PAMs and Marc-145 cells {#sec0070}
----------------------------------------------------------------------------

PAMs were infected with PRRSV at various multiplicities of infection (MOI) for 24 h; qRT-PCR was performed to quantitate the level of S100A9 mRNA and viral N protein gene expression. The results showed that the level of S100A9 mRNA was upregulated by PRRSV in a dose-dependent manner ([Fig. 1](#fig0005){ref-type="fig"} A).Fig. 1PRRSV infection induces S100A9 in PAM and Marc-145 cells. (A) PAMs were infected with the PRRSV BB0907 strain for 24 h. qRT-PCR was used to quantitate the level of S100A9 and N protein mRNA expression. (B) Marc-145 cells were infected with 0.1 MOI of the BB0907 strain for 12 h, 24 h, 36 h, and 48 h. The qRT-PCR was used to quantitate the level of S100A9 and N protein mRNA expression. (C) Western blot analysis was used to determine the level of S100A9 and N protein expression. All of the results are expressed as the means + standard deviation from three independent experiments.Fig. 1

MARC-145 cells were infected with PRRSV (0.1 MOI) for 12 h, 24 h, 36 h, and 48 h. Then a Western blot and qRT-PCR were used to determine the effect of PRRSV infection on S100A9 expression in Marc-145 cells. The results revealed that PRRSV infection significantly promoted both the level of S100A9 mRNA and protein expression from 24 to 48 hpi ([Fig. 1](#fig0005){ref-type="fig"}B and C). These results indicated that PRRSV infection promotes S100A9 expression.

3.2. S100A9 inhibits PRRSV replication {#sec0075}
--------------------------------------

To explore whether S100A9 affects the replication of PRRSV, Marc-145 cells were transfected with pCI-S100A9-HA for 24 h, then incubated with 0.01 MOI PRRSV for 12 h, 24 h, and 36 h. A western blot and qRT-PCR assay analysis showed that the level of PRRSV N protein was significantly decreased in cells overexpressing S100A9 compared with those in the empty vector-transfected cells at all-time points ([Fig. 2](#fig0010){ref-type="fig"} A, and C). TCID~50~ assay also showed that PRRSV titers were obviously decreased in cells overexpressing S100A9 ([Fig. 2](#fig0010){ref-type="fig"}B).Fig. 2S100A9 inhibits PRRSV replication. (A) Western blot assay for N protein of Marc-145 cells transfected with pCI-S100A9-HA or an empty vector for 24 h, and then infected with the PRRSV BB0907 strain (0.01 MOI), for 24 h, 36 h, and 48 h. (B) The level of N protein mRNA expression by qPCR and (C) PRRSV titer by TCID~50~ assay. (D) Western blot of Marc-145 cells transfected with three siRNAs targeting monkey *S100A9*. (E―G) Western blot, qRT-PCR, and TCID~50~ of Marc-145 cells transfected with siRNA3 for 24 h, then infected with the PRRSV BB0907 strain for 36 h. (H―J) Western blot, qRT-PCR, and TCID~50~ of Marc-145 cells transfected with pCI-S100A9-HA or control vector for 24 h, then infected with the PRRSV strains BB0907, S1, and FJ1402 for 36 h. All results are expressed as the means + standard deviations from three independent experiments.Fig. 2

The silencing efficiency of three siRNAs targeting monkey *S100A9* was tested in Marc-145 cells and examined by western blot. As shown in [Fig. 2](#fig0010){ref-type="fig"}D, siRNA3 was the most efficient at decreasing the expression of endogenous S100A9. Then Marc-145 cells transfected with 50 nM siRNA3 and subsequently infected with PRRSV (0.01 MOI) exhibited greater expression of PRRSV N protein compared with the cells transfected with the negative siRNA control (NC) ([Fig. 2](#fig0010){ref-type="fig"}E). Moreover, the qRT-PCR and TCID~50~ data also revealed that the knockdown of S100A9 was beneficial for viral proliferation ([Fig. 2](#fig0010){ref-type="fig"}F and G). In addition, S100A9 overexpression inhibited the proliferation of classical PRRSV strain (C-PRRSV), S1, and the epidemic NADC30-like strain, FJ1402 ([Fig. 2](#fig0010){ref-type="fig"}H--J).

3.3. S100A9 inhibition of PRRSV replication is dependent on intracellular Ca^2+^ {#sec0080}
--------------------------------------------------------------------------------

Because S100A9 contains two EF hand calcium-binding domains, we hypothesized that calcium could affect the antiviral activity of S100A9. Firstly, the cytotoxicity of BAPTA was tested. The result showed that BAPTA, at concentration as high as 80 μM for 48 h, did not show cytotoxicity toward Marc-145 cells ([Fig. 3](#fig0015){ref-type="fig"} A), as determined by Cell Counting Kit-8. Then Marc-145 cells were transfected with pCI-S100A9-HA, subsequently treated with BAPTA for 24 h, and infected with PRRSV for another 36 h. The cells treated with BAPTA had significantly higher levels of PRRSV N-protein expression in a dose dependent manner compared to untreated cells, as shown by western blot and qRT-PCR ([Fig. 3](#fig0015){ref-type="fig"}B and C). Additionally, a TCID~50~ assay showed that chelating intracellular Ca^2+^ resulted in increased PRRSV proliferation in infected cells overexpressing S100A9 ([Fig. 3](#fig0015){ref-type="fig"}D). This finding demonstrated that the activity of S100A9 against PRRSV propagation was dependent on intracellular Ca^2+^.Fig. 3S100A9 inhibition of PRRSV replication is dependent on intracellular Ca^2+^. Marc-145 cells were transfected with pCI-S100A9-HA for 6 h, then treated with BAPTA (10 μM, 30 μM, and 50 μM), and infected with PRRSV an MOI of 0.01 for 36 h. Cells were lysed and analyzed by (A) western blot, (B) real time PCR, and (C) TCID~50~ assay. All the results were confirmed by three independent experiments. Error bars represent the standard deviations of triplicate experiments.Fig. 3

3.4. S100A9 interacts with the PRRSV N protein {#sec0085}
----------------------------------------------

To screen for viral proteins that interact with S100A9, HEK293 T cells were co-transfected with pCI-S100A9-HA and recombinant plasmids expressing PRRSV Nsp1α, Nsp1β, Nsp4, Nsp5, Nsp7, Nsp9-12, GP5, M, and N protein genes. The Co-IP results showed that S100A9 efficiently co-precipitated with only the N protein ([Fig. 4](#fig0020){ref-type="fig"} A and B). To visualize the interaction between S100A9 and the N protein, Marc-145 cells were transfected with pCI-S100A9-HA for 24 h, then infected with PRRSV at an MOI of 0.1 36 hpi. Confocal microscopy showed the co-localization of S100A9 (red) and N protein (green) in the cytoplasm. Infection with PRRSV did not alter the distribution of S100A9 ([Fig. 4](#fig0020){ref-type="fig"}C).Fig. 4S100A9 interacts with the PRRSV N protein. HEK293T cells were co-transfected with pCI-S100A9-HA and plasmids encoding PRRSV proteins (nsp1α, nsp1β, nsp4, nsp5, nsp7, nsp9-12, GP5, M, and N) for 30 h then prepared for immunoprecipitation by (A) an anti-FLAG antibody or (B) anti-HA antibody. (C) Immunoﬂuorescence assay of Marc-145 cells transfected with pCI-S100A9-HA or vector for 24 h, then infected with PRRSV for 30 h. The S100A9 (red) N protein (green) and nuclei (blue). All the results were confirmed by three independent experiments. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 4

3.5. The key amino acids of the PRRSV N protein are required for the interaction with S100A9 {#sec0090}
--------------------------------------------------------------------------------------------

To determine the region of the N protein that interacts with S100A9, a series of plasmids expressing a mutant N protein were co-transfected with pCI-S100A9-HA. Co-IPs were performed, and the results showed that S100A9 co-precipitated with all of the mutated N proteins except for Q33-5A ([Fig. 5](#fig0025){ref-type="fig"} A-C), indicating that the S100A9 interacting region of the viral N protein is located at amino acids 33--37. Five plasmids expressing separate point mutations within this region of the N protein were constructed. Co-IP analysis showed that S100A9 efficiently co-precipitated with the mutations Q33A, N34A, and Q35A, but not S36A and R37A ([Fig. 5](#fig0025){ref-type="fig"}D), which demonstrated that S36 and R37 are the key amino acids necessary for the interaction between the viral N protein and S100A9.Fig. 5The key region of the PRRSV N protein necessary for the interaction with S100A9. (A--D) HEK293 T cells co-transfected for 30 h with pCI-S100A9-HA and pCI*-N-*FLAG or the pCI-N\*-FLAG series of plasmids, the proteins were immunoprecipitated by an anti-FLAG antibody. Whole cell lysates and IP complexes were analyzed by western blot using anti-FLAG and HA antibodies. (E) The growth kinetics of the wild type PRRSV BB0907 strain and recombinant PRRSV rBB(36/37). (F--H) Marc-145 cells transfected with pCI-S100A9-HA or empty vector followed by an incubation with 0.01 MOI of BB0907 or rBB(36/37). A western blot (F), qPCR (G), and TCID~50~ assay (H) were used to determine the level of viral replication. The data are expressed as the means + standard deviations from three independent experiments.Fig. 5

To confirm the role of S36 and R37 in the viral N protein, a recombinant virus, rBB (36/37), was constructed and rescued from the infectious clone, pCMV-BB0907, as previously described (Fig. S2) ([@bib0140]). The growth kinetics of rBB (36/37) in Marc-145 cells was similar to that of the parent strain, BB0907 ([Fig. 5](#fig0025){ref-type="fig"}E). The antiviral activity of S100A9 against the recombinant virus, rBB (36/37), was significantly decreased compared with that against the parent BB0907 as determined by western blot, qPCR, and TCID~50~ assay ([Fig. 5](#fig0025){ref-type="fig"}F-H).

3.6. The key amino acids of S100A9 are necessary for its interaction with the PRRSV N protein {#sec0095}
---------------------------------------------------------------------------------------------

To investigate the S100A9 amino acids that affect PRRSV replication, a series of plasmids expressing mutations in S100A9 were constructed and co-transfected with pCI-N into HEK293 T cells. The Co-IP results showed that only the mutant E78Q did not co-precipitate with the N protein, demonstrating that E78 is the key amino acid involved in the interaction between S100A9 and PRRSV ([Fig. 6](#fig0030){ref-type="fig"} A). Thereafter, Marc-145 cells were transfected with plasmids expressing mutated S100A9 for 24 h, then infected with PRRSV at an MOI of 0.01. As shown in [Fig. 6](#fig0030){ref-type="fig"}B and C, S100A9 with the E78Q mutation displayed significantly less antiviral activity than wild type S100A9. These results demonstrated that E78 was an amino acid required for the anti-PRRSV activity of S100A9.Fig. 6The key region of S100A9 is necessary for the interaction with PRRSV N protein. (A) Western blot of HEK293T cells co-transfected with plasmids expressing pCI-S100A9 or pCI-S100A9(E78Q) and pCI*-N-*FLAG or empty vector for 30 h. The proteins were immunoprecipitated by an anti-HA antibody. The whole cell lysates and IP complexes were analyzed with an anti-FLAG or HA antibody. (B and C) Marc-145 cells transfected with plasmids expressing mutants of S100A9 for 24 h, then infected with 0.01 MOI of the PRRSV BB0907 strain for 36 h. Viral replication was analyzed by western blot and qPCR. The data are expressed as the means + standard deviations from three independent experiments.Fig. 6

3.7. S100A9 inhibits PRRSV replication in PAMs {#sec0100}
----------------------------------------------

Porcine alveolar macrophages (PAMs) are the target cells of PRRSV. To investigate the effect of S100A9 on PRRSV replication in PAMs, three siRNAs targeting porcine S100A9 were designed. As shown in [Fig. 7](#fig0035){ref-type="fig"} A, siRNA-3 was found to be the most effective at silencing the expression of endogenous S100A9, reducing it by 50 %. A transfection with siRNA-3 significantly enhanced PRRSV replication compared with that of the control siRNA ([Fig. 7](#fig0035){ref-type="fig"}B and C). Next, two recombinant lentiviruses, LV-S100A9 and LV-S100A9(E78Q), expressing S100A9 and S100A9(E78Q), respectively, were constructed and rescued. PAMs were transduced with recombinant lentiviruses at an MOI of 10 following infection with PRRSV BB0907 or rBB(36/37) at an MOI of 0.01. These results showed that PRRSV BB0907 strain replication was significantly restricted in LV-S100A9-transduced PAMs, whereas PRRSV rBB(36/37) replication was not ([Fig. 7](#fig0035){ref-type="fig"}D and E).Fig. 7S100A9 inhibits PRRSV replication in PAMs. (A) The qRT-PCR of PAMs transfected with siRNA targeting porcine *S100A9* or non-specific siRNA. (B and C) Viral replication in PAMs transfected with siRNA-3 or non-specific siRNA for 24 h then infected with 0.01 MOI of PRRSV BB0907, measured by western blot and qPCR. (D--G) Viral replication in PAMs transduced with a lentivirus expressing S100A9 or S100A9(E78Q), (LV-S100A9 and LV-S100A9(E78Q)) and an empty vector (LV-vector). The cells were then infected with 0.01 MOI of PRRSV BB0907 or rBB(36/37), and expression was measured by Western blot and qRT-PCR. The data are expressed as the means + standard deviations from three independent experiments.Fig. 7

Additionally, the replication of the BB0907 strain was significantly limited in both LV-S100A9 and LV-S100A9(E78Q)-transduced PAMs. However, the level of viral replication in LV-S100A9(E78Q)-transduced cells was notably reversely increased compared to those in LV-S100A9 transduced cells, as demonstrated by western blot and qRT-PCR assays ([Fig.7](#fig0035){ref-type="fig"}F and G). These results demonstrated that S100A9 inhibited PRRSV replication in PAMs. In addition, the E78 in S100A9 played an important role in the regulation of PRRSV replication.

4. Discussion {#sec0105}
=============

PRRSV displays a high degree of genetic and antigenic heterogeneity, which poses a continuous challenge for disease control and results in tremendous economic losses to pork producers throughout the world ([@bib0170]; [@bib0215]). Although commercial vaccines are available, they provide only limited protection. Pattern recognition receptors (PRRs) play a sentinel role in the activation of the innate immune system by detecting pathogen associated molecular patterns (PAMPs) associated with viruses and bacteria ([@bib0085]). PRRs include host restriction factors, many of which are simulated by interferon, which directly or indirectly target multiple stages of the viral life cycle. For instance, the membrane-associated enzyme, cholesterol 25-hydroxylase, inhibits viral entry and degrades viral proteins ([@bib0050]; [@bib0100]). Moreover, viperin (an IFN-stimulated gene) suppresses HCMV infection by inhibiting viral structural protein synthesis, assembly, and maturation ([@bib0035]). Viperin also destroys lipid rafts, inhibiting the budding and release of influenza virus ([@bib0200]). TRIM family proteins also interfere at multiple stages of the viral life cycle, including degrading viral proteins ([@bib0060]), decreasing gene expression and impeding viral assembly ([@bib0005]; [@bib0205]); however, as an immunosuppressive virus, PRRSV can negatively regulate the host immune response to promote viral propagation via several pathways, including multiple interferon-pathway suppression ([@bib0105]; [@bib0010]; [@bib0120]), host antiviral protein degradation ([@bib0070], [@bib0080]), disturbance of monocyte/macrophages, B cell, and T cell development ([@bib0075]; [@bib0150]; [@bib0055]), and reduced expression of antigen presenting molecules ([@bib0025]). In the present study, we found that HP-PRRSV infection promoted S100A9 expression in both PAMs and Marc-145 cells. The overexpression and knockdown of S100A9 demonstrated that S100A9 has significant antiviral activity against PRRSV infection. Moreover, the antiviral activity of S100A9 depended on the presence of cellular calcium.

The PRRSV N protein is a vital structural protein required for viral replication. Our previous reports revealed that the viral N protein is associated with the production of CD83 ([@bib0020], [@bib0030]), Treg cells ([@bib0055]), and IL-10 ([@bib0145]), which play an important role in virus-induced immunosuppression. A study by Zhao et al., found that the PRRSV N protein could decrease the antiviral activity of TRIM25 by interfering with TRIM25-mediated RIG-I ubiquitination ([@bib0220]). In the present study, to identify viral proteins that interact with S100A9 and the functional sites of such interactions, we constructed a series of plasmids expressing PRRSV proteins. Co-IP assays showed only the viral N protein was immunoprecipitated by S100A9, and amino acids 36--37 of the N protein were necessary and sufficient for the interaction. Furthermore, recombinant PRRSV rBB(36/37) with the mutations S36A and R37A in the N protein was constructed. It was confirmed that 36--37 aa of the viral N protein represented the key region at which the viral N protein interacted with S100A9.

DAMPs are host-derived molecules that serve to initiate and perpetuate the innate immune response. The calcium-binding protein, S100A9, belongs to the S100 protein family, and functions as a DAMP. Generally, S100A9 binds to its respective receptor, including RAGE, TLR2, and TLR4, to activate NF-κB or the MAPK signaling pathways ([@bib0110]; [@bib0155]). A recent study revealed that some DAMPs are also involved in the regulation of PRRSV replication. For example, HP-PRRSV infection promotes S100A6 expression in PAMs, which is related to the activity of NF-κB activation by HP-PRRSV ([@bib0230]). Additionally, the inhibition of endogenous HSP70 and HSP90 can attenuate PRRSV replication ([@bib0045]; [@bib0065]); however, there are few reports investigating the role of S100A9 in viral infection. Some previous studies indicate that S100A9 could be induced by poly I:C stimulation ([@bib0185]), and human papillomavirus infection also increases S100A9 production ([@bib0180]). Similarly, the level of S100A9 in patients infected with coronavirus was also upregulated by more than 60-fold ([@bib0165]). Because S100A9 is a part of several important immune pathways, it becomes the logical target for viral proteins to interfere with host defense mechanisms. To identify the key region by which S100A9 interacts with the viral N protein, we constructed a series of plasmids expressing S100A9 mutants. The results showed that only the mutant E78Q did not co-precipitate with the N protein and had significantly less antiviral activity compared to the wild type S100A9. Moreover, similar results were also obtained in experiments with PAMs using the recombinant lentiviruses, LV-S100A9 and LV-S100A9(E78Q). These results demonstrated that the E78Q mutation caused a significant decrease in the antiviral activity of S100A9. Moreover, E78 is an S100A9 amino acid necessary for its anti-PRRSV activity.

In summary, we found that S100A9 exhibited prominent anti-PRRSV activity that was dependent on the level of cellular Ca^2+^. S100A9 inhibits PRRSV replication by interacting with the PRRSV N protein. In addition, E78 in S100A9 played an important role in the regulation of PRRSV replication. These findings provide insight into the host defense mechanisms mediated against PRRSV infection, which should be useful for developing strategies for the control of PRRSV infection.
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